1. Home
  2. Detail

@mohamerabet9: #تحفيز #motivation #foryour #fvp

motivation 🕊️ 💪
motivation 🕊️ 💪
Open In TikTok:
Region: DZ
Wednesday 18 June 2025 03:55:40 GMT
405405
10705
66
2891

Music

Download

No Watermark .mp4 (3.69MB) No Watermark(HD) .mp4 (3.21MB) Watermark .mp4 (7.52MB) Music .mp3

Comments

mysteriousman910
mysteriousman91 :
I'll take it.👍
2025-06-18 15:42:47
2
zezoxakt76q
عبدالعزيز حسن :
أوقف الإنسانية التي داخلي وايقظ الوحش الذي داخلي ٢٠٢
2025-06-20 08:17:56
6
ghufran.alkhwad.al
Ghufran Alkhwad Altom :
من المتحدث الانجليزي ولا اروع
2025-07-24 10:56:24
0
laya_146
Lena :
100%👍🏼
2025-07-01 17:37:57
0
a.m.e.e.r.a6
🐰 🎀 𝒶𝓂𝑒𝑒𝓇𝒶 🎀 🐰 :
the painful truth thanks for these words
2025-07-08 18:53:18
0
khaledxinag
Khaled Xiang :
عندي جزء في عقلي حتى انا نخاف منه
2025-07-02 21:58:51
1
meme09251
Hudhud :
رساله لكل شخص بحياتي
2025-06-19 08:18:44
2
22320like
الحياة حلوه :
thank you my friend
2025-06-18 03:58:25
2
miramora46
محمد الاميرmiramora46 :
أنها ثقتى بنفسى فانا اعمل جاهدا لكى احافظ عليها
2025-07-20 17:22:36
0
arassalhellalle
Arass :
اتمنى يكون الاحترام فعلا متبادل
2025-06-26 14:01:20
1
butterfly....jjj2
Rose 🌹 :
perfect words 👌
2025-06-30 11:55:10
0
user9115887151163
ملكة الكلمات :
never ever.
2025-06-18 20:24:32
2
llkh_29
KhAliFaalMalKi💫 :
كثرة الضغط ايولد الانفجار = واذا انفجرت اضر العموم العدو والصديق والغريب والبعيد شضاية الانفجار تطوول الجميع بلاه استثناء 👌🏽
2025-06-29 00:20:53
0
user9102815598373
user9102815598373 :
ī love your words 🥰🥰🥰
2025-06-18 11:16:39
3
kembar2203
الشمري Kembar 2203 :
نعم.
2025-06-19 22:29:48
2
user4948812068723
بارق :
نريد نشوف صاحب الصوت 😂😂😂😂
2025-07-01 22:06:59
0
mhdi232323
ابوكنوز :
🥰🥰
2025-06-19 23:49:14
2
ch.dorai
Ch.dorai :
🥰🥰🥰
2025-06-20 13:06:35
1
tyqbq1778
MínaMína :
👏👏👏👏👏
2025-06-19 21:38:07
1
user216774547765
جمال شعبان :
🥰🥰🥰
2025-06-18 23:37:35
1
amalamou13
𝐀𝐦𝐚𝐥/امل 🕊️♾️🙏 :
❤❤❤
2025-06-18 14:24:26
1
cheriguiabdjalil
abdeljalil :
🥰🥰🥰
2025-06-18 12:31:31
1
faresblue4
Le F :
💕💕💕💕💕
2025-06-18 08:32:38
1
faresblue4
Le F :
💕💕
2025-06-18 08:32:33
1
faresblue4
Le F :
🥰🥰
2025-06-18 08:32:29
1
To see more videos from user @mohamerabet9, please go to the Tikwm homepage.

Other Videos

Let’s review the OASIS-4 trial results presented at ASCO and published in the New England Journal of Medicine. This study evaluates elinzanetant for vasomotor symptoms (hot flashes and night sweats) in patients with breast cancer (stage 0-3) on endocrine therapy (either tamoxifen or an aromatase inhibitor). Elinzanetant blocks two brain receptors, NK1 and NK3, which are involved in regulating body temperature. It is a non hormonal option. It is in same class of meds as Veozah but this is the first study study results we have of looking at this med in patients w breast cancer. Participants were randomized into 2 groups: elinzanetant or placebo x12 weeks and then elinzanetant. 316 participants were in the elinzanetant group and 158 in the placebo- elinzanetant group. The dose of elinzanetant is 120 mg daily. At baseline, the average daily frequency of moderate to severe vasomotor symptoms was 11.4 episodes in the elinzanetant group. At 4 weeks: the mean change from baseline in the average daily frequency of moderate-to-severe vasomotor symptoms was -6.5 episodes in elinzanetant group and -3.0 episodes in placebo group (there’s a placebo effect!). At 12 weeks: the mean change from baseline in the average daily frequency of moderate-to-severe vasomotor symptoms was -7.8 episodes in elinzanetant group and -4.2 episodes in placebo group. Elinzanetant also resulted in greater improvement in sleep disturbances and menopause related quality of life. In exploratory analyses, more than 70% of the participants treated with elinzanetant had a reduction in symptoms of at least 50% at 12 weeks Headaches, joint pain and nausea were seen in both groups (but in no more than ~10-12% of participants). Somnolence, fatigue, and diarrhea were reported more frequently with elinzanetant than with placebo during weeks 1 through 12. No deaths occurred during the trial. Majority of the participants in this study were White which limits the applicability of the results and while patients at risk of breast cancer were allowed, only 1 patient on study was taking endocrine therapy to reduce the risk of breast cancer. The tentative deadline for the FDA to make a decision is end of July 2025 so we will see if this becomes an option! Let me know your questions! What has been your experience with hot flashes? #elinzanetant #breastcancer #hotflashes #menopause #menopausetok #nightsweats #oncologist
Let’s review the OASIS-4 trial results presented at ASCO and published in the New England Journal of Medicine. This study evaluates elinzanetant for vasomotor symptoms (hot flashes and night sweats) in patients with breast cancer (stage 0-3) on endocrine therapy (either tamoxifen or an aromatase inhibitor). Elinzanetant blocks two brain receptors, NK1 and NK3, which are involved in regulating body temperature. It is a non hormonal option. It is in same class of meds as Veozah but this is the first study study results we have of looking at this med in patients w breast cancer. Participants were randomized into 2 groups: elinzanetant or placebo x12 weeks and then elinzanetant. 316 participants were in the elinzanetant group and 158 in the placebo- elinzanetant group. The dose of elinzanetant is 120 mg daily. At baseline, the average daily frequency of moderate to severe vasomotor symptoms was 11.4 episodes in the elinzanetant group. At 4 weeks: the mean change from baseline in the average daily frequency of moderate-to-severe vasomotor symptoms was -6.5 episodes in elinzanetant group and -3.0 episodes in placebo group (there’s a placebo effect!). At 12 weeks: the mean change from baseline in the average daily frequency of moderate-to-severe vasomotor symptoms was -7.8 episodes in elinzanetant group and -4.2 episodes in placebo group. Elinzanetant also resulted in greater improvement in sleep disturbances and menopause related quality of life. In exploratory analyses, more than 70% of the participants treated with elinzanetant had a reduction in symptoms of at least 50% at 12 weeks Headaches, joint pain and nausea were seen in both groups (but in no more than ~10-12% of participants). Somnolence, fatigue, and diarrhea were reported more frequently with elinzanetant than with placebo during weeks 1 through 12. No deaths occurred during the trial. Majority of the participants in this study were White which limits the applicability of the results and while patients at risk of breast cancer were allowed, only 1 patient on study was taking endocrine therapy to reduce the risk of breast cancer. The tentative deadline for the FDA to make a decision is end of July 2025 so we will see if this becomes an option! Let me know your questions! What has been your experience with hot flashes? #elinzanetant #breastcancer #hotflashes #menopause #menopausetok #nightsweats #oncologist
لا تلمنى فلا يلام الجريح. #خالد_الراشد
لا تلمنى فلا يلام الجريح. #خالد_الراشد
#ابوعجيب #قروب_ابو_حصه #😂😂😂 #viralvideo #goviral
#ابوعجيب #قروب_ابو_حصه #😂😂😂 #viralvideo #goviral
- م ابي اخسرك ! #اقتباسات #خذلان #fyp #fypシ #التفكير_الزائد #فصحتي #كتابات_فصحى #خريف🌒 #200k?
- م ابي اخسرك ! #اقتباسات #خذلان #fyp #fypシ #التفكير_الزائد #فصحتي #كتابات_فصحى #خريف🌒 #200k?
سويله تاك . . . #اللهم_صلي_على_نبينا_محمد #اكسبلورexplore #fypシ #100k #هاشتاق
سويله تاك . . . #اللهم_صلي_على_نبينا_محمد #اكسبلورexplore #fypシ #100k #هاشتاق
💦 #foryoupage #4upage #fypシ #foryou
💦 #foryoupage #4upage #fypシ #foryou

About

Legal